Work

Non-Alcoholic Fatty Liver Disease as a Systemic Metabolic Disorder

Year: 2026
Type: article
Abstract: Non-alcoholic fatty liver disease (NAFLD), now largely encompassed by metabolic dysfunction-associated steatotic liver disease (MASLD), is the hepatic expression of a broader disturbance in adipose-tissue function, insulin action, substrate flux, inflammation, and vascular risk. Its clinical importance extends well beyond progression from steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Cardiovascular disease remains a major competing cause of morbidity and death, while type 2 diabetes, chronic kidney disease, heart failure, selected extrahepatic cancers, sarcopenia, and sleep-related breathing disorders interact bidirectionally with liver injury. This narrative review synthesizes evidence published from January 2018 through August 2026, including current nomenclature statements, international practice guidance, population studies, diagnostic validation studies, clinical trials, and mechanistic research. The review examines metabolic substrate overload, selective insulin resistance, lipotoxicity, mitochondrial and endoplasmic-reticulum stress, innate immune activation, gut-liver signaling, hepatokines, and fibrogenesis as links between hepatic and systemic disease. It emphasizes risk-based case finding rather than population-wide screening, sequential use of fibrosis-4 followed by elastography or specialized biomarkers, and management directed at overall cardiometabolic risk as well as liver fibrosis. Lifestyle treatment, weight reduction, physical activity, statins when indicated, optimized diabetes and obesity therapy, bariatric procedures in selected patients, and liver-directed pharmacotherapy are considered within an integrated pathway. Resmetirom has established a liver-targeted treatment option for selected noncirrhotic patients with fibrotic steatohepatitis, while phase 2 and phase 3 data for incretin-based and fibroblast growth factor 21-directed therapies continue to reshape the field. The central conclusion is that NAFLD/MASLD should be managed as a systemic metabolic disorder with fibrosis-informed liver care, aggressive cardiovascular prevention, and longitudinal multidisciplinary follow-up rather than as an isolated abnormality of liver enzymes or imaging.
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7217103498
FWCI:
Cites: 50
Cited by:
Related to: 10